Stichting Elisabeth-Tweesteden Ziekenhuis — Clinical Trial Site

107 Registered trials

52 Currently recruiting

Organisation

Stichting Elisabeth-Tweesteden Ziekenhuis

Location

Tilburg, Netherlands

Identifier

ORG-100031075

Address

Hilvarenbeekseweg 60, 5022 GC, Netherlands

Departments

031003: Oncology
2604:Cardiology
3706: Cardiology
5001:Pulmonology
Alimentary Tract and Metabolism
Cardiology
Department of Gastroenterology & hepatology
Department of Gastroenterology and Hepatology
Department of Medical Oncology
Department of Oncology
Department of Pulmonary Diseases
Gastroeneterology
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and hepatology
Hematology
Intensive Care
internal medecine
Internal Medicine
Internal Oncology
Interne Geneeskunde
Interne geneeskunde - Oncologie
Longgeneeskunde
Maag-, Darm- en Leverziekten
Maag-, darm,- en leverziekten / Gastroenterology and Hepatology
MDL
Medical Oncology
N/A
NA
Neurology
Neurosurgery
NL10001: Internal medicine
Oncology
Oncology-Hematology
Oncology/Hematology
Ophthalmology
Orthopedic surgery
orthopedics
Orthopedie
Pulmonary medicine
Pulmonology
Pulmonology department
Reproductive medicine and gynecology
Rheumatology
Surgery
Trialoffice Oncology-Hematology
Vascular Surgery

Clinical trials at this site (107)

Search interface

A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
Low dose ColchicinE in pAtients with peripheral artery DiseasE to address residual vascular Risk: A randomized trial- LEADER PAD Recruiting

2024-512091-35-01 Peripheral arterial disease 5 2025-06-17
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting

2024-517343-31-00 Ischemic stroke and transient ischemic attack 6 2025-04-11
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Crohn's disease 4 2025-04-07
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L… Recruiting

2023-505311-20-01 Metastatic Non-Small Cell Lung Cancer 5 2025-03-21
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
BuLLSEYE Recruiting

2024-512950-13-00 Sepsis 11 2025-01-03
Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance Recruiting

2023-507489-20-00 Statin-intolerance 6 2024-12-10
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting

2024-513092-40-00 Stroke 6 2024-12-05
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting

2023-510395-31-00 Metabolic Dysfunction-Associated Steatohepatitis (MASH) 5 2024-10-30
DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting

2023-510186-98-00 Venous thromboembolism 6 2024-10-23
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi… Recruiting

2024-514620-17-00 Patients with early-stage rectal cancer (defined as ear 4 2024-10-14
Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH) Recruiting

2024-514927-40-02 Chronic Subdural Hematoma 11 2024-10-01
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting

2023-509096-16-00 Moderately to Severely Active Crohn’s Disease 6 2024-07-31
CLEAR-PATH trial Recruiting

2024-513363-15-01 (Chronic) Peripheral (occlusive) arterial disease (PAD) 11 2024-07-22
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting

2022-500305-40-00 Small Lymphocytic Lymphoma 9 2024-04-10